<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01730612</url>
  </required_header>
  <id_info>
    <org_study_id>BRD/10/04-O</org_study_id>
    <nct_id>NCT01730612</nct_id>
  </id_info>
  <brief_title>ImmunoTEP au 68-Ga- IMP-288 for Patients With a Recurrence of HER2 Negative Breast Carcinoma Expressing CEA</brief_title>
  <acronym>iTEPsein</acronym>
  <official_title>Pilot Study for Optimization of Immuno-PET Pretargeted With Anti-CEA Bispecific Antibody X Anti-HSG TF2 and the Peptide IMP-288 Radiolabeled With Gallium-68 -Pharmacokinetic and Imaging for Patients With a Recurrence of HER2 Negative Breast Carcinoma Expressing CEA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Main objective: To determine the optimal molar doses of the biospecific antibody TF2 and 68&#xD;
      Ga-IMP-288 and the optimal time for pretargeting for immuno-PET in patients with breast&#xD;
      carcinoma.&#xD;
&#xD;
      Secondary objectives: To study the sensitivity of the immuno-PET, compare its performance to&#xD;
      standard imaging methods, evaluate the safety of 150 MBq of 68 Ga-IMP-288; study the&#xD;
      development of immunization against TF2 or complex TF2-IMP-288;&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  4 or 5 cohorts of 3 patients receiving different doses of TF2 IMP-288 with different&#xD;
           interval time. A last cohort (4 or 5 ): maximum of 21 additional patients with the&#xD;
           optimal schedule.&#xD;
&#xD;
      Cohort I: TF2 120 nmol / 6 nmol IMP-288 / 24 hours&#xD;
&#xD;
      Cohort II: based on the results of the cohort I :&#xD;
&#xD;
        1. Good signal of the tumor but high background: increased interval time, 120 nmol TF2 / 6&#xD;
           nmol of IMP-288 / 30 hours&#xD;
&#xD;
        2. Low signal of the tumor: reduction of the interval time, 120 nmol TF2 / 6 nmol IMP-288 /&#xD;
           18 hours&#xD;
&#xD;
        3. Good signal of the tumor and good background signal : dose reduction, 60 nmol TF2 /&#xD;
           3nmol IMP- 288 / 24 hours&#xD;
&#xD;
           Cohort III: based on results of cohort II:&#xD;
&#xD;
           - Good signal of the tumor : dose reduction, 120 nmol TF2 / 3 nmol IMP-288 / 30 h&#xD;
&#xD;
           Cohort IV : based on results of cohort III Cohort V : Based on results of cohort IV&#xD;
&#xD;
           • A last Cohort (VI) : 19 patients with the optimal schedule of injection : 120 nmol TF2&#xD;
           / 3 nmol IMP-288 / 30 h or 120 nmol TF2 / 6 nmol IMP-288 / 30 h&#xD;
&#xD;
           • In the four weeks prior to the immuno-PET:&#xD;
&#xD;
           - Clinical examination,&#xD;
&#xD;
           - CEA and CA15-3,&#xD;
&#xD;
           - thoraco abdominal pelvic scan, bone scan, FDG-PET,&#xD;
&#xD;
           - immunohistochemistry ACE on the tumor if possible,&#xD;
&#xD;
           - Anti-Antibodies if the patient has already received MAb,&#xD;
&#xD;
           - pregnancy test within 2 days prior to immuno-PET,&#xD;
&#xD;
           - (creatinine &gt; 2.5 normal) D0: Injection of TF2 D1 to D4: injection of 68 Ga-IMP-288&#xD;
           (depending of the cohort) D0 to D4 : pharmacokinetics, imaging&#xD;
&#xD;
           Evaluation at 1 month of Immuno-PET:&#xD;
&#xD;
           • Assessment of the clinical oncologist and&#xD;
&#xD;
           - histological biopsy and / or surgery performed according to the results of imaging and&#xD;
           assessment of the potential clinical impact&#xD;
&#xD;
           Evaluation at 3 and 6 months of immuno-PET:&#xD;
&#xD;
           based on the results of immuno-PET, evaluation and therapeutic decision of the&#xD;
           oncologist,&#xD;
&#xD;
           - Imaging (ultrasound, bone scintigraphy, CT or PET FDG),&#xD;
&#xD;
           - markers&#xD;
&#xD;
             -  Anti-Antibody Search&#xD;
&#xD;
             -  For patient with a cancer treatment a new immuno-PET can be proposed&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>evaluation of the tumor targeting (no Unit) and signal / noise ratio (no unit) by the immunoTEP with TF2 and 68-Ga-IMP-288</measure>
    <time_frame>One week</time_frame>
    <description>Pk blood after injections of TF2 and 68 Ga-IMP-288 and PET imaging semi-quantification with 60 to 120 minutes after injection of 68 Ga-IMP-288</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensibility, tolerance</measure>
    <time_frame>6 months after immunoTEP</time_frame>
    <description>sensitivity of the immuno-PET and compare its performance to standard imaging methods, pathological data if available data or imaging follow-up of at least 6 months by RECIST and EORTC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To study the contribution of immnoTEP to assess early response to treatment, compare its performance to standard imaging methods</measure>
    <time_frame>month 6</time_frame>
    <description>6 weeks after initiation of treatment of metastases (after the first iTEP), a second _iTEP with a therapeutic evaluation will be carried out. The examination requirements are identical to those of the first immunoTEP.&#xD;
this second iITEP will be evaluated in regard of imaging assessment performed routinely (TAP scanner, FDG-PET, CA15-3 and CEA)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>• To assess the tolerance of 150 MBq of 68 Ga-IMP-288</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>To search for the development of immunization with TF2 and the complex TF2-IMP-288: ELISA</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <enrollment type="Actual">23</enrollment>
  <condition>HER2 Negative Breast Carcinoma Expressing CEA</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TF2 - 68 Ga-IMP-288:</intervention_name>
    <description>ImmunoTEP</description>
    <other_name>TF2: trivalent recombinant humanized antibody recognizing the ACE and the peptide histamine-succinyl-glycine IMP-288 (HSG)</other_name>
    <other_name>68 Ga-IMP-288: di-HSG peptide-DOTA-labeled with Gallium 68</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Breast carcinoma, HER2 + (Dako) and HER2 + (fish) metastatic at least after treatment&#xD;
             with current consensus&#xD;
&#xD;
          -  ≥ 18 years&#xD;
&#xD;
          -  Negative pregnancy test for women of childbearing age. Women of childbearing age&#xD;
             should take effective contraception continuously for 3 months.&#xD;
&#xD;
          -  Karnofsky ≥ 70 or ECOG 0-1&#xD;
&#xD;
             •• ACE of the tumor by immunohistochemistry or positive plasma CEA ≥ 10 ng / mL&#xD;
&#xD;
          -  At least one measurable lesion on CT&#xD;
&#xD;
          -  creatinine &lt; 2.5&#xD;
&#xD;
          -  Informed consent signed&#xD;
&#xD;
          -  Social insurance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
               -  Serious illness or co-morbidity risk assessed&#xD;
&#xD;
               -  History of cancer within 5 years except skin cancer other than melanoma or&#xD;
                  carcinoma in situ of the cervix&#xD;
&#xD;
               -  Presence of anti-antibodies in patients who have previously received antibodies&#xD;
&#xD;
               -  Known hypersensitivity to antibodies or proteins&#xD;
&#xD;
               -  intellectual disability to sign the informed consent&#xD;
&#xD;
               -  Not controlled diabetes&#xD;
&#xD;
               -  Persons protected by law&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>francoise Bodere, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nantes Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>November 12, 2012</study_first_submitted>
  <study_first_submitted_qc>November 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2012</study_first_posted>
  <last_update_submitted>July 26, 2018</last_update_submitted>
  <last_update_submitted_qc>July 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ImmunoTEP</keyword>
  <keyword>HER2 negative</keyword>
  <keyword>Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Histamine</mesh_term>
    <mesh_term>Glycine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

